Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double blind, Placebo Controlled Trial to Evaluate the protective efficacy of three doses of Oral Rotavirus Vaccine (ORV) 116E, against severe Rotavirus gastroenteritis in infants.

Trial Profile

A Phase III, Randomized, Double blind, Placebo Controlled Trial to Evaluate the protective efficacy of three doses of Oral Rotavirus Vaccine (ORV) 116E, against severe Rotavirus gastroenteritis in infants.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORV 116E (Primary) ; Diphtheria tetanus and pertussis vaccine; Hepatitis B vaccine; Measles vaccines; Poliovirus vaccine live oral; Tuberculosis vaccine
  • Indications Rotavirus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Bharat Biotech; PATH
  • Most Recent Events

    • 12 Mar 2015 Based on data from this trial, the rotavirus vaccine ORV 116E [ROTAVAC] has been approved and launched in India, according to a Bharat Biotech media release.
    • 12 Mar 2014 Results published in the Lancet online
    • 14 May 2013 Results published in a Bharat Biotech media release and presented at the International Symposium on Rotavirus Vaccines for India.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top